Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conventional versus hypofractionated radiotherapy plus temozolomide in elderly glioblastoma
KCT0007527Phase 3Recruiting
- Sponsor
- Yonsei University Health System
- Start
- Dec 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of temozolomide in glioblastoma (GBM), sponsored by Yonsei University Health System. Started Dec 2025; status: recruiting.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on KCT0007527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007527.